FDA Pushes for Accelerated Approval of Gene Therapies

The head of the Center for Biologics Evaluation and Research at the FDA, Peter Marks, has said that the agency needs to start using accelerated approval to advance gene therapies for rare diseases. Marks said that the FDA can't be so careful about approvals under accelerated approval that it prevents potentially lifesaving therapies from getting to market in a timely manner.